What did @kaylakayyy0 actually say?
In her week five update, @kaylakayyy0 reported losing eight pounds total since starting compounded semaglutide through Eden Health. She said she's "moving up a dose to a point five" and keeping her injection site around the belly, with no notable side effects. She also described visible changes to her jawline, waistline, and arms.
This is a pretty standard GLP-1 progress video: personal results, a dose update, and a partner link in the bio. What she's describing tracks with how semaglutide actually works in the early weeks, though there are a few things worth unpacking, particularly around compounded versus brand-name drug equivalency and what "no side effects" really tells us about her experience so far.
Does the science back this up?
Eight pounds in five weeks is plausible, especially early in treatment, but it sits at the higher end of what clinical trials report on average. Still, individual variation is real and well-documented.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. Early weeks tend to produce faster loss as water weight and glycogen stores drop before fat loss takes over. A loss of roughly 1.5 lbs per week in weeks one through five is consistent with that early-phase pattern, though averages mask how wide the range actually is. Some people lose faster, some slower, and neither is a reliable predictor of long-term outcomes. The belly as an injection site is also consistent with clinical guidance, which lists the abdomen, thigh, and upper arm as acceptable sites for subcutaneous injection of semaglutide.
What did they get wrong (or right)?
Mostly right on the mechanics. The dose escalation she describes, starting low and titrating up, is exactly how semaglutide is supposed to work. Going too fast is a known driver of nausea and GI side effects, so starting conservatively is legitimate practice, not a red flag.
The part that deserves scrutiny is the framing around side effects. She says she's "not experiencing any crazy symptoms or side effects, which is amazing." That's genuinely good news for her, but it could mislead viewers into thinking side effects are rare. They're not. In the STEP trials, over 70% of participants reported GI events including nausea, vomiting, and diarrhea. Many people do tolerate semaglutide well, particularly at lower doses, but presenting a side-effect-free experience as the likely norm without context is a gap worth noting.
She also doesn't distinguish between compounded semaglutide and FDA-approved brand-name products. These are not equivalent. The FDA has issued warnings about compounded semaglutide, noting that compounded versions lack the same manufacturing oversight and bioavailability data as Ozempic or Wegovy.
What should you actually know?
If you're considering semaglutide, the clinical evidence for weight loss is genuinely strong, but the specifics of how you access it matter more than most influencer content suggests.
Compounded semaglutide became widely available after Ozempic and Wegovy faced shortage designations. The FDA allowed compounding during that window, but also made clear that compounded drugs are not FDA-approved and that quality can vary by pharmacy. As of early 2025, the FDA has stated that the shortage has resolved and that compounded semaglutide may no longer qualify for the compounding exemption going forward. That regulatory situation is still evolving.
Davies et al. (2021, Lancet) and the broader STEP program data confirm that semaglutide's effectiveness depends heavily on consistent dosing, lifestyle factors, and medical supervision. An eight-pound loss at week five is encouraging, but it says nothing about whether someone will maintain that loss, manage side effects at higher doses, or be on the right product formulation in the first place. If you're going to start a GLP-1, talk to a licensed provider who can review your full health history, not just a telehealth intake form triggered by a TikTok link.